Barrington Research Raises Henry Schein (NASDAQ:HSIC) Price Target to $92.00

Henry Schein (NASDAQ:HSIC) had its price target increased by Barrington Research from $90.00 to $92.00 in a research report released on Wednesday morning, Benzinga reports. The firm currently has an outperform rating on the stock. Barrington Research also issued estimates for Henry Schein’s Q2 2024 earnings at $1.27 EPS, Q3 2024 earnings at $1.31 EPS, Q4 2024 earnings at $1.42 EPS, FY2024 earnings at $5.10 EPS, Q1 2025 earnings at $1.14 EPS, Q2 2025 earnings at $1.34 EPS, Q3 2025 earnings at $1.39 EPS, Q4 2025 earnings at $1.59 EPS and FY2026 earnings at $6.00 EPS.

HSIC has been the subject of several other reports. Piper Sandler upped their target price on Henry Schein from $78.00 to $86.00 and gave the company an overweight rating in a report on Monday, February 26th. JPMorgan Chase & Co. raised their target price on Henry Schein from $82.00 to $88.00 and gave the company an overweight rating in a research report on Wednesday, March 6th. Evercore ISI boosted their price target on shares of Henry Schein from $79.00 to $83.00 and gave the stock an in-line rating in a report on Wednesday, February 28th. Jefferies Financial Group lifted their price objective on shares of Henry Schein from $74.00 to $81.00 and gave the stock a hold rating in a research report on Wednesday, March 6th. Finally, SVB Leerink assumed coverage on shares of Henry Schein in a research report on Monday, February 26th. They set a market perform rating and a $78.00 target price for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Henry Schein currently has an average rating of Hold and a consensus price target of $81.73.

Henry Schein Stock Performance

Shares of HSIC traded up $0.86 during midday trading on Wednesday, reaching $73.62. 170,296 shares of the stock were exchanged, compared to its average volume of 1,097,360. The stock’s 50 day simple moving average is $73.01 and its 200 day simple moving average is $72.34. Henry Schein has a twelve month low of $60.01 and a twelve month high of $82.63. The company has a quick ratio of 1.00, a current ratio of 1.67 and a debt-to-equity ratio of 0.45. The company has a market cap of $9.46 billion, a P/E ratio of 23.10, a PEG ratio of 1.68 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.09. Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.21 billion. During the same quarter last year, the company posted $1.21 EPS. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. On average, sell-side analysts expect that Henry Schein will post 5.07 earnings per share for the current year.

Insider Activity

In other news, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the sale, the insider now owns 209,562 shares in the company, valued at approximately $15,585,125.94. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the sale, the insider now directly owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bradford C. Connett sold 6,430 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares in the company, valued at approximately $5,430,462.24. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

Institutional Investors Weigh In On Henry Schein

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Boston Partners lifted its position in shares of Henry Schein by 144.1% in the fourth quarter. Boston Partners now owns 2,637,429 shares of the company’s stock worth $199,393,000 after buying an additional 1,556,831 shares in the last quarter. Norges Bank purchased a new position in shares of Henry Schein in the fourth quarter valued at $111,715,000. Nuance Investments LLC bought a new stake in Henry Schein in the fourth quarter worth $103,446,000. Lazard Asset Management LLC raised its stake in Henry Schein by 1,303.3% during the third quarter. Lazard Asset Management LLC now owns 1,247,334 shares of the company’s stock valued at $92,614,000 after purchasing an additional 1,158,451 shares in the last quarter. Finally, Fiduciary Management Inc. WI lifted its position in Henry Schein by 17.1% during the fourth quarter. Fiduciary Management Inc. WI now owns 2,284,337 shares of the company’s stock valued at $172,947,000 after purchasing an additional 333,855 shares during the last quarter. 96.62% of the stock is owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.